Design and formulation of Digoxin by Liquisolid technique using volatile solvents and evaluation of content uniformity of formulation with the digoxin tablets in the market

Abstract

Introduction: Digoxin is one of the drugs used in the treatment of heart disease to increase the contractile power and pumping of the heart. This drug is very strong and has a very low therapeutic dose and a very narrow treatment window, so the uniformity of the drug dose in the drug form is very important. the biggest challenge in the formulation of this drug is the very low dose of this drug, so the uniform distribution of the drug in the granules containing the drug is very important. Aim: Performance evaluation of liquisolid system in Increasing the content uniformity of Digoxin Method and material: For this purpose, the solubility of the drug in several non-volatile solvents was investigated. Liquisolid formulations were prepared with permissible volatile solvents of pharmaceuticals, carriers, coatings, and common excipients for the manufacture of tablets such as lubricants, compressibility enhancers, and materials that improve the physicochemical properties of tablets. Formulations prepared in terms of drug content uniformity were analyzed high performance liquid chromatography and then drug dose in formulations was calculated by FDA guidelines for determining drug dose uniformity by software written in Excel and with each other as well as with validly samples Digoxin was traded in the market. Results: The results showed that Dose uniformity in liquisolid formulations prepared with volatile solvent is much better than that of liquid-to-solid formulations prepared with non-volatile solvents, and especially to formulations prepared by simple physical mixing. Conclusion: The liquisolid method can produce dose uniformity better than formulations prepared by traditional methods. Volatile solvents can perform much better than non-volatile solvents at creating a uniform dose of digoxin.